A maker of nutritional supplements and personal care products, sold under the Nature's Sunshine Products and Synergy WorldWide brands through a network of independent consultants in regions from Asia to the Americas. It all started in 1972 when Gene Hughes, trying cayenne pepper for a digestive ailment, found it awful to swallow by the spoonful — so he and his wife Kristine hand-filled the powder into gelatin capsules at their kitchen table in Utah, an approach that helped launch the modern supplement industry. The company's name reflects its mission of sharing the healing power of nature.
Nature's Sunshine appoints Ruth Perkins as EVP and CFO, effective September 1, 2026
Perkins will receive an annual base salary of $575,000 and a target bonus of 70% of base salary.
Show detailsHide details
Ruth Perkins appointed Executive Vice President and Chief Financial Officer, effective September 1, 2026.
She will receive equity awards with an aggregate target value of approximately $1.65 million within ten days of employment.
Perkins has over 20 years of finance leadership experience, including at The Estée Lauder Companies, PepsiCo, and Ford.
Jon Lanoy will continue as Principal Accounting Officer.
2.02 Results of Operations and Financial Condition · 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 9.01 Financial Statements and Exhibits
Nature's Sunshine CFO L. Shane Jones resigns; Jonathan D. Lanoy named interim principal financial officer.
Jones's resignation was not due to any disagreement with the company on financial reporting or accounting matters.
Show detailsHide details
L. Shane Jones notified the company on May 8, 2026, of his resignation as CFO and Principal Financial Officer, effective June 5, 2026.
Jonathan D. Lanoy, 51, was appointed Interim Principal Financial Officer on May 8, 2026; he continues as SVP, Chief Accounting Officer, and Principal Accounting Officer.
Lanoy's employment agreement provides an annual base salary of $301,551 and a target annual bonus of 50% of base salary.
If terminated without cause, for good reason, or due to death/incapacity, Lanoy is entitled to 12 months of severance and COBRA reimbursement, subject to a release and restrictive covenants.
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 9.01 Financial Statements and Exhibits
Nature's Sunshine shareholders approve 2026 Stock Incentive Plan at annual meeting
All eight director nominees were elected, including Steven Fasching, Curtis Kopf, Katie May, Tess Roering, Kenneth Romanzi, Robert Straus, Heidi Wissmiller, and Rong Yang.
Show detailsHide details
On May 6, 2026, shareholders approved the 2026 Stock Incentive Plan, effective immediately, authorizing up to 1,500,000 shares of common stock for issuance.
Shareholders approved, on an advisory basis, executive compensation with 11,288,205 votes for and 779,056 against.
Shareholders ratified Deloitte & Touche LLP as independent auditor for 2026 with 14,619,306 votes for.
The 2026 Stock Incentive Plan was approved with 6,357,245 votes for and 5,723,107 against.
2.02 Results of Operations and Financial Condition · 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits
Nature's Sunshine reports Q4 and FY2025 results; CFO and EVP Asia receive salary increases
Q4 2025 net sales rose 4.7% to $123.8 million; GAAP net income was $4.1 million ($0.23 per diluted share) vs. a net loss of $0.3 million a year ago.
Show detailsHide details
Full-year 2025 net sales increased 5.7% to $480.1 million; GAAP net income was $19.5 million ($1.06 per diluted share) vs. $7.7 million in 2024.
Adjusted EBITDA for Q4 2025 was $11.9 million (up 16%) and for full-year 2025 was $49.4 million (up 21.7%).
CFO L. Shane Jones's base salary increased from $478,400 to $492,752, effective March 8, 2026.
EVP Asia Dan Norman's base salary increased from $446,250 to $459,638, effective March 8, 2026.
2.02 Results of Operations and Financial Condition · 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 9.01 Financial Statements and Exhibits
Nature's Sunshine appoints Kenneth Romanzi as CEO, effective October 29, 2025.
Terrence O. Moorehead will resign on October 29, 2025, under a separation agreement dated October 10, 2025.
Show detailsHide details
Kenneth Romanzi, age 65, will become CEO and join the Board of Directors on October 29, 2025.
Romanzi's employment agreement provides an $850,000 annual base salary and RSU awards with a combined fair value of $3,000,000.
Moorehead will receive 18 months of estimated base salary, a pro-rated 2025 bonus, and continued RSU vesting during the severance period.
Romanzi brings over 40 years of CPG experience, including as CEO of B&G Foods.
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
Nature's Sunshine Reports Q2 2025 Net Sales Up 4% to $114.8M
Net sales for Q2 2025 were $114.8 million, up 4% from $110.6 million in the year-ago quarter.
Show detailsHide details
GAAP net income attributable to common shareholders was $5.3 million, or $0.28 per diluted share, compared to $1.3 million, or $0.07 per diluted share, in Q2 2024.
Adjusted EBITDA increased 8% to $11.3 million from $10.4 million in the prior year quarter.
The company raised its full-year 2025 outlook, now expecting net sales between $460-$475 million and adjusted EBITDA between $41-$45 million.
As of June 30, 2025, the company had $81.3 million in cash and cash equivalents and zero debt.
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
Nature's Sunshine to buy Fosun's JV interests for $7.0M total
On June 30, 2025, Nature's Sunshine Products entered into share purchase agreements with Fosun Industrial to repurchase Fosun's 20% interests in two China joint ventures.
Show detailsHide details
The Hong Kong Joint Venture interest will be acquired for $3.9 million in cash, and the Shanghai Joint Venture interest for $3.1 million in cash.
The repurchase was triggered because Fosun Pharma's affiliate sold 2,854,607 shares on June 27, 2025, dropping Fosun's ownership below 5% of Nature's Sunshine's outstanding common stock.
Closing is subject to customary conditions, including regulatory submissions to the PRC State Administration for Market Regulation and the PRC Ministry of Commerce.
The purchase agreements are filed as Exhibits 10.1 and 10.2 to the Form 8-K.
1.01 Entry into a Material Definitive Agreement · 9.01 Financial Statements and Exhibits